References
- Van Bruggen FH, Nijhuis GBJ, Zuidema SU, et al. Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review. Expert Rev Clin Pharmacol. 2020;13:787–796.
- Department of Health and Human Services. Clinical trials registration and results information submission. Washington: NIH; 2016.
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
- Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015;351:h4320.
- Tse T, Williams RJ, Zarin DA. Reporting “basic results” in ClinicalTrials.gov. Chest. 2009;136:295–303.
- Sabatine MS, Giugliano RP, Schwartz GG. Letter to the Editor re: “Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review”. Exp Rev of Clin Pharmacol. 2021;14(02):1–5.
- Sullivan G, Feinn R. Using effect size—or why the P value is not enough. J Grad Med Educ. 2012;4:279–282.
- Lantz B. The large sample size fallacy. Scand J Caring Sci. 2013;27:487–492.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107.
- [cited 2020 Nov 8]. Available from: https://www.escardio.org/static-file/Escardio/About%20the%20ESC/Annual-Reports/ESCAnnualReport2020-BD.pdf
- [cited 2020 Nov 8]. Available from: https://www.eas-society.org/page/corporate_partners
- [cited 2020 Nov 8]. Available from: https://www.escardio.org/static-file/Escardio/Guidelines/DOI/DOI_Summary_2019_DYSLIPIDAEMIAS.pdf